183 related articles for article (PubMed ID: 16107239)
1. Promising systemic therapy for renal cell carcinoma.
Cooney MM; Remick SC; Vogelzang NJ
Curr Treat Options Oncol; 2005 Sep; 6(5):357-65. PubMed ID: 16107239
[TBL] [Abstract][Full Text] [Related]
2. Novel agents for the treatment of advanced kidney cancer.
Cooney MM; Remick SC; Vogelzang NJ
Clin Adv Hematol Oncol; 2004 Oct; 2(10):664-70. PubMed ID: 16163253
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the systemic treatment of metastatic papillary renal cancer.
Chowdhury S; Choueiri TK
Expert Rev Anticancer Ther; 2009 Mar; 9(3):373-9. PubMed ID: 19275514
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
5. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
[TBL] [Abstract][Full Text] [Related]
6. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
[TBL] [Abstract][Full Text] [Related]
7. [Value of targeted therapies for renal cell cancer].
Merseburger AS; Kuczyk MA
Urologe A; 2008 Oct; 47(10):1303-10. PubMed ID: 18587556
[TBL] [Abstract][Full Text] [Related]
8. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ; Bukowski RM
J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
[TBL] [Abstract][Full Text] [Related]
10. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
[TBL] [Abstract][Full Text] [Related]
11. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Subbiah V; Slopis J; Hong DS; Ketonen LM; Hamilton J; McCutcheon IE; Kurzrock R
J Clin Oncol; 2012 Feb; 30(5):e64-8. PubMed ID: 22203760
[No Abstract] [Full Text] [Related]
13. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
Flaig TW; Costa LJ; Gustafson DL; Breaker K; Schultz MK; Crighton F; Kim FJ; Drabkin H
Br J Cancer; 2010 Sep; 103(6):796-801. PubMed ID: 20823888
[TBL] [Abstract][Full Text] [Related]
14. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
de Mulder PH; Haanen JB; Sleijfer S; Kruit WH; Gietema JA; Richel DJ; Groenewegen G; Voest EE; van den Eertwegh AJ; Osanto S; Jansen RL; Mulders PF
Ned Tijdschr Geneeskd; 2008 Feb; 152(7):371-5. PubMed ID: 18380383
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
16. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Barbastefano J; Garcia JA; Elson P; Wood LS; Lane BR; Dreicer R; Campbell SC; Rini BI
BJU Int; 2010 Nov; 106(9):1266-9. PubMed ID: 20346042
[TBL] [Abstract][Full Text] [Related]
17. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
Ravaud A; Digue L; Trufflandier N; Smith D
Ann Oncol; 2010 Feb; 21(2):431-432. PubMed ID: 19945958
[No Abstract] [Full Text] [Related]
18. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
19. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Richards TM; Plowman PN; Reznek R; Ball SA
Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
[No Abstract] [Full Text] [Related]
20. Treatment options for metastatic renal cell carcinoma: a review.
Athar U; Gentile TC
Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]